Medical Crossfire®: Moving the Field Forward with DOAC Reversal Agents

Released On
July 31, 2019

Expires On
July 31, 2020

Media Type
Internet

Completion Time
90 minutes

Specialty
Cardiology, Critical Care, Emergency Medicine, Hematology, Hospitalist, Neurology

Topic(s)
DOAC Reversal

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians' Education Resource®, LLC.

 

This activity is supported by an educational grant from Portola Pharmaceuticals, Inc.

Credit Available

  • Physicians — maximum of 1.5 AMA PRA Category 1 Credit(s)

All other health care professionals completing this course will be issued a statement of participation.

Activity Overview

The field of direct oral anticoagulant (DOAC) reversal agents is relatively new. A known adverse event among all anticoagulation therapies is increased risk of bleeding following therapy. Any bleeding patient on an anticoagulant should be risk-stratified based on hemodynamic instability, source of bleeding, and degree of blood loss. Many questions surround the implementation of reversal agents into practice including which clinician patients should seek when bleeding occurs. This activity, titled "Medical Crossfire®: Moving the Field Forward with DOAC Reversal Agents," will cover the clinical need for reversal agents, current guidelines on reversal therapies, and the role of clinicians across several disciplines and the clinical implications within each therapeutic area.

Benefits of Participating

  • Gain insights into the importance of addressing bleeding risks following anticoagulant therapy and into the mechanisms of action of DOAC agents
  • Improve competence regarding the integration of novel therapies into the management of thromboembolic disease and the use of reversal agents following bleeding episodes
  • Increase awareness of multidisciplinary strategies in the care of patients on anticoagulation therapy

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review video files/content until you finish the presentation.
  • At the end of the activity, educational content/video files will be available for your reference.
  • In order to receive a CME/CE certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME/CE certificate upon completion of these steps.

Target Audience

This online educational activity is directed toward emergency medicine physicians, nurses, hospitalists, cardiologists, neurologists, hematologists, and other healthcare professionals interested in the treatment of patients in need of DOAC reversals.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Evaluate the bleeding risk of patients on DOAC therapy and the mechanisms of action of different agents
  • Assess the efficacy and safety of reversal agents for DOAC therapy
  • Develop strategies to bridge gaps in management of patients on DOAC therapy

Faculty, Staff, and Planners’ Disclosures

Charles V. Pollack Jr, MD, MA, FACEP, FAAEM, FAHA, FACC, FESC

Adjunct Professor of Emergency Medicine
Lewis Katz School of Medicine
Temple University
Philadelphia, PA

Disclosures: Grants/Research Support: Boehringer Ingelheim, CSL Behring, Daiichi Sankyo, Janssen, Portola Pharma; Consultant: Boehringer Ingelheim, Janssen, Portola Pharma.

Deepak L. Bhatt, MD, MPH

Executive Director of Interventional Cardiovascular Programs
Brigham and Women’s Hospital
Professor of Medicine
Harvard Medical School
Boston, MA

Disclosures: Grants/Research Support: Abbott, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, Eisai, Ethicon, Forest Laboratories, Idorsia, Ironwood Pharmaceuticals, Ischemix, Lilly, Medtronic, PhaseBio, Pfizer, Regeneron, Roche, Sanofi-Aventis, Synaptic, The Medicines Company.

Krishna Gundabolu, MD, FACP

Associate Professor, Department of Hematology-Oncology
Director of the Thrombosis and Hemostasis Program
University of Nebraska Medical Center
Omaha, NE

Disclosures: Stockholder: Portola Pharmaceuticals.

Edward M. Manno, MD, MS

Vice Chair of Clinical Affairs
Department of Neurology
Northwestern University Feinberg School of Medicine
Director of the Neurological Intensive Care Unit, Northwestern Memorial Hospital
Chicago, IL

Disclosures: Edward Manno has no relevant financial relationships with commercial interests to disclose.

The staff of Physicians' Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.

Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Instructions for Participation and Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review video files/content until you finish the presentation.
  • At the end of the activity, educational content/video files will be available for your reference.
  • In order to receive a CME/CE certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME/CE certificate upon completion of these steps.

Hardware and Software Requirements

This site is best viewed with an HTML5 compatible browser. You can visit the independent (3rd party) site www.whatismybrowser.com to determine if you have the latest version of your browser.

Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, and Real Networks Real One Player.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Disclosure of Unlabeled Use

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of PER® or any of the companies that provided commercial support for this program.